This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of LPH-5.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence and severity of adverse events (AEs)
Timeframe: Through study completion, an average of 1 year
Incidence of laboratory abnormalities, based on hematology, clinical chemistry, and urinalysis test results
Timeframe: Through study completion, an average of 1 year
Incidence of abnormal clinical laboratory findings in 12-lead ECG parameters, vital signs, and physical examination
Timeframe: Through study completion, an average of 1 year